Analytical Data
-
基因名
MAGEA5
- Application
-
别名
MAGEA5P;MAGE5;MAGEA5;Putative melanoma-associated antigen 5P
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P43359
-
表达区间
1-124aa
-
氨基酸序列
MGSSHHHHHH SSGLVPRGSH MGSHGASAIPTAID FTLWRQSIKG SSNQEEEGPS TSPDPESVFR AALSKKVADL IHFLLLKYMSLEQK SQHCKPEEGL DTQEEALGLV GVQAATTEEQ EAVSSSSPLV PGTLGEVPAA GSPGPLKSPQ
-
分子量
16 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Recombinant Human KLHL18 Protein，GST
Cat：PA2000-8746
Recombinant Human MAGEA4 Protein，His
Cat：PA1000-1874
Protein Description
MAGEA5, a member of the MAGE (Melanoma Antigen Gene) family, is a cancer/testis antigen primarily expressed in various tumors and limited normal tissues, making it an attractive target for cancer immunotherapy. Unlike many antigens, MAGEA5 is not found in normal somatic cells, which heightens its potential as a therapeutic target for tumor-specific treatments while mitigating the risk of off-target effects in healthy tissues. Research on MAGEA5 recombinant proteins has gained traction due to their potential applications in vaccine development and personalized cancer therapy. The immunogenic properties of MAGEA5 have been investigated in various studies, highlighting its capability to elicit robust T-cell responses in cancer patients. Moreover, MAGEA5’s expression correlates with various malignancies, including melanoma, lung, and prostate cancers, indicating its role in tumor immunogenicity. By generating recombinant MAGEA5 proteins, researchers aim to study its structural and functional properties, contributing to the development of novel immunotherapeutic strategies. This includes the potential design of peptide-based vaccines and adoptive T-cell therapies that specifically target MAGEA5-expressing tumors. Overall, the study of MAGEA5 recombinant proteins holds promise for advancing our understanding of tumor-specific antigens and enhancing the effectiveness of cancer immunotherapies.
